H2 2026: Prudence and New Focus Amidst the AI Investment Boom
As the second half of 2026 unfolds, the global investment community is experiencing a subtle yet profound shift. Over the past few years, "pure AI" concept stocks and startups have garnered unprecedented attention and massive investments. However, market concerns about an AI "bubble" are growing. Multiple reports indicate a significant mismatch between the huge investment in AI infrastructure and actual application revenue. For example, as of September 2026, AI industry expenditure reached $400 billion, but revenue was only $60 billion, with OpenAI reportedly losing as much as $12 billion per quarter.
This phenomenon has prompted institutional investors to become more discerning. They are no longer solely pursuing "growth at all costs" but are instead focusing on projects that can deliver real revenue, user retention, measurable return on investment (ROI), and possess proprietary data or distribution advantages. The high failure rate of enterprise AI projects primarily stems from practical challenges such as data quality, talent shortages, security vulnerabilities, and integration barriers, rather than the algorithms themselves.
Medical Technology: A New Growth Point Driven by AI Integration
It is against this backdrop that the medical technology sector, especially sub-sectors deeply integrated with AI, is emerging as a "hidden gem" and an alternative growth driver for institutional investors. PwC expects that in the second half of 2026, M&A activity in the medical technology sector will remain robust, with strategic acquirers reshaping portfolios around sustainable growth, breakthrough technologies, and ecosystem capabilities.
AI applications in healthcare have transitioned from experimental innovations to mainstream technology. In 2025, total venture capital in healthcare AI in the US and Europe approached $18 billion, accounting for 46% of all healthcare investments. This trend accelerated in 2026, with investment activities concentrated in high-growth areas such as chronic disease management, home healthcare, and workforce training. The biopharmaceutical sector also maintained its lead, with venture capital reaching $12.6 billion in H1 2026.
Concurrently, the regulatory environment for medical AI is maturing. As of July 2025, the U.S. Food and Drug Administration (FDA) had authorized over 1,250 AI medical devices for clinical use, a significant increase from a year prior, providing a clearer path and confidence for the commercialization of AI medical technology.
Institutional Investor Strategy Shift and Specific Cases
Institutional investors in the medical technology sector favor companies with strong clinical data, commercial momentum, or both. Corporate Venture Capital (CVC) is also increasingly active, with large enterprises funding high-growth areas such as robotics, diagnostics, and AI infrastructure through their venture capital arms.
Specific cases show that medical technology startups continue to receive substantial funding:
- Neuralink (Brain-Computer Interface): Cumulative funding has reached $1.3 billion.
- OpenEvidence (AI Medical Search): Raised $317 million.
- PROCEPT BioRobotics (Surgical Robotics): Q1 2026 revenue of $83.1 million, a 20% year-over-year increase.
- AliveCor (Smart ECG): Cumulative funding of approximately $318 million.
- Earendil Labs (AI Drug Discovery): Raised $787 million.
These examples indicate that capital is flowing towards projects that combine AI technology with actual medical needs and demonstrate a clear path to commercialization. Investors generally believe that the growth of medical technology increasingly relies on commercial and clinical execution, rather than merely technological releases. For related developments, please refer to Svmuu's ongoing reports.
Future Outlook and Risk Warnings
Despite the immense potential of the medical technology sector, investors must remain cautious. Successful integration of AI in healthcare requires not only algorithmic innovation but also innovation in supporting infrastructure such as validation, regulation, economics, and clinical adoption. Simultaneously, challenges such as cybersecurity, data privacy, cost control, and cultural resistance persist.
In summary, in the second half of 2026, institutional investors are shifting from a blind pursuit of "pure AI" to a more refined allocation in "AI + vertical sectors," with medical technology becoming a new favorite in the capital market due to its unique value and growth potential. This does not signify the end of the AI boom but rather its entry into a more pragmatic and mature development phase.
